VINC News and Press, Vincera Pharma Inc Com From 04/09/24

2024-04-09 08:26:39 ET More on Pre-market losers & stocks. HUB Cyber Security jumps 39% on QPoint Technologies acquisition Acorda Therapeutics announces Nasdaq delisting notification Financial information for Acorda Therapeutics Financial information for ...

VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic (PK) data shows very little free payload in circulation, consist...

2024-04-07 19:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-05 10:01:19 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Top ...

2024-04-02 07:53:14 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vincerx Pharma (NASDAQ: VINC ) just reported results for the fourth quarter of 2023. Vincerx Pharma reported earnings per share of -23 cents. This was above the analyst es...

PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, will host a virtual investor event reviewing preliminary clinical data...

2024-04-01 01:04:26 ET More on Vincerx Pharma Vincerx Pharma stock rises on positive efficacy data from lymphoma therapy Seeking Alpha’s Quant Rating on Vincerx Pharma Historical earnings data for Vincerx Pharma Financial information for Vincerx Pharma...

VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM PT Phase 1 trial ongoing for VIP943, a best-in-class anti-CD123 antibody-drug conjugate...

Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...

2024-03-19 12:48:26 ET More on Mid-day movers & stocks. Ontrak Health announces continuing expansion with Sentara Health Sarcos Technology and Robotics says co-founder Ben Wolff to become CEO Financial information for Aptorum Group Seeking Alpha’s ...